The power of patient voice in clinical trial design
The increased patient-centric focus in drug development by the FDA is highly encouraging and expected to become more mainstream and legislated.
Report: IBM is ending sales of Watson for Drug Discovery
IBM is stopping the development and sales of the product, which uses Watson AI to help pharmaceutical companies find new drugs, because it wasn't yielding large enough financial returns, according to a STAT report.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Why pharma is starting to think more like Amazon
As pharma continues to close the gap between the operational and analytical needs of their business, they can look to other industries for best practices.
Five innovation trends that will impact the healthcare industry in 2019
The behavioral health epidemic, artificial intelligence and more procedures being done in outpatient settings are some the key 2019 trends that will determine how decision makers purchase technology.
Biopharma needs a new R&D, innovation model
Strategic partnerships are one way for biopharmaceutical companies to expand capabilities and offerings and proactively define their future versus having it defined for them.
What do CMIOs think of medication management initiatives?
A new survey found chief medical information officers believe medication management improvement initiatives have positively impacted patient safety, but factors like workflow variation and a lack of price transparency still compromise patients' well-being.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Pharma is making inroads into digital health, albeit slowly
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
The potential for conflict of interest when health policy experts also serve on the boards of pharma companies
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
presented by
Roche acquires the rest of Foundation Medicine for $2.4B, supporting its precision medicine strategy
It's the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma's drug development business, particularly in cancer treatment.
FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Drugmakers increasingly target “baskets” of tumors based on mutations
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
Trump’s drug cost cutting plans include transparency, but critics doubt much will change
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.
Martin Shkreli’s in prison but Daraprim prices are still high
Shkreli, 35, is serving a seven-year prison term for securities fraud (unrelated to Daraprim). Turing has renamed itself Vyera Pharmaceuticals. But Daraprim, which costs pennies to make and is used to treat the parasitic infection toxoplasmosis still retails for more than $750 per pill, according to drug website GoodRx.com.
A look at how one pharma company responded to the pressure on drug prices: Ramping up political activity
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
FDA’s Scott Gottlieb highlights digital health initiatives from new incubator to AI at Health Datapalooza
At the ninth annual Health Datapalooza conference in Washington D.C. this week, Scott Gottlieb also provided an update on the pre-certification program, which is scheduled to launch before the end of the year.